SG11202105125XA - Macrocyclic compound and use thereof - Google Patents
Macrocyclic compound and use thereofInfo
- Publication number
- SG11202105125XA SG11202105125XA SG11202105125XA SG11202105125XA SG11202105125XA SG 11202105125X A SG11202105125X A SG 11202105125XA SG 11202105125X A SG11202105125X A SG 11202105125XA SG 11202105125X A SG11202105125X A SG 11202105125XA SG 11202105125X A SG11202105125X A SG 11202105125XA
- Authority
- SG
- Singapore
- Prior art keywords
- macrocyclic compound
- macrocyclic
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018228234 | 2018-12-05 | ||
PCT/JP2019/048593 WO2020116660A1 (en) | 2018-12-05 | 2019-12-04 | Macrocyclic compound and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202105125XA true SG11202105125XA (en) | 2021-06-29 |
Family
ID=70975488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202105125XA SG11202105125XA (en) | 2018-12-05 | 2019-12-04 | Macrocyclic compound and use thereof |
Country Status (17)
Country | Link |
---|---|
US (1) | US11518763B2 (en) |
EP (1) | EP3890738A4 (en) |
JP (1) | JP2022510736A (en) |
KR (1) | KR20210099622A (en) |
CN (1) | CN113164468A (en) |
AR (1) | AR117251A1 (en) |
AU (1) | AU2019391942B2 (en) |
BR (1) | BR112021010704A2 (en) |
CA (1) | CA3121952A1 (en) |
CL (1) | CL2021001451A1 (en) |
CO (1) | CO2021007304A2 (en) |
MX (1) | MX2021006527A (en) |
PH (1) | PH12021551262A1 (en) |
SG (1) | SG11202105125XA (en) |
TW (1) | TWI820266B (en) |
UA (1) | UA127872C2 (en) |
WO (1) | WO2020116660A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA126950C2 (en) | 2018-08-20 | 2023-02-22 | Янссен Фармацевтика Нв | Inhibitors of keap1-nrf2 protein-protein interaction |
KR20230104126A (en) * | 2020-09-14 | 2023-07-07 | 사노피 | Tetrahydroisoquinoline derivatives for the treatment of red blood cells and inflammatory diseases |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2606622C2 (en) | 2010-08-31 | 2017-01-10 | Бионуре Фарма, С.Л. | Agonists of neurotrophin receptors and their use as medicaments |
EP3010892B8 (en) | 2013-06-21 | 2019-05-22 | Karyopharm Therapeutics Inc. | 1,2,4-triazoles as nuclear transport modulators and uses thereof |
CA2934216C (en) | 2013-12-18 | 2021-03-16 | Glaxosmithkline Intellectual Property Development Limited | Substitued phenyl or benzyl propanote derivatives and pharmaceutical compositiions thereof useful as nrf2 regulators |
PT3307739T (en) | 2015-06-15 | 2021-01-04 | Glaxosmithkline Ip Dev Ltd | Nrf2 regulators |
CA2988374A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
RU2018101077A (en) | 2015-06-15 | 2019-07-15 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | REGULATORS NRF2 |
CA2995325A1 (en) | 2015-08-12 | 2017-02-16 | Mochida Pharmaceutical Co., Ltd. | Isothiazole derivative |
US10351530B2 (en) | 2015-10-06 | 2019-07-16 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as NRF2 regulators |
JP2018529745A (en) | 2015-10-06 | 2018-10-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Biarylpyrazoles as NRF2 regulators |
US20200031820A1 (en) | 2016-12-12 | 2020-01-30 | Glsxosmithkline Intellectual Property Development Limited | 3-carboxylic acid pyrroles as nrf2 regulators |
WO2018109642A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
ES2848699T3 (en) | 2016-12-14 | 2021-08-11 | Glaxosmithkline Ip Dev Ltd | 3-Oxo-1,4-diazepinyl compounds as activators of NRF2 |
US11078216B2 (en) | 2016-12-14 | 2021-08-03 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl amides as NRF2 activators |
WO2018109643A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl heterocycles as nrf2 acti |
US11059816B2 (en) | 2016-12-15 | 2021-07-13 | Glaxosmithkline Intellectual Property Development Limited | Ether linked triazoles as NRF2 activators |
CN110114361B (en) | 2016-12-15 | 2022-04-12 | 葛兰素史密斯克莱知识产权发展有限公司 | NRF2 compound |
AR110590A1 (en) | 2016-12-27 | 2019-04-10 | Biogen Ma Inc | NRF2 ACTIVATOR |
WO2018140738A1 (en) | 2017-01-30 | 2018-08-02 | Biogen Ma Inc. | Nrf 2 activator |
EP3573968A1 (en) * | 2017-01-30 | 2019-12-04 | Biogen MA Inc. | Nrf2 activator |
JP2020097526A (en) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | Heterocyclic compound |
-
2019
- 2019-12-04 KR KR1020217020790A patent/KR20210099622A/en active Search and Examination
- 2019-12-04 CN CN201980080214.5A patent/CN113164468A/en active Pending
- 2019-12-04 CA CA3121952A patent/CA3121952A1/en active Pending
- 2019-12-04 AR ARP190103549A patent/AR117251A1/en unknown
- 2019-12-04 JP JP2021554804A patent/JP2022510736A/en active Pending
- 2019-12-04 SG SG11202105125XA patent/SG11202105125XA/en unknown
- 2019-12-04 BR BR112021010704-5A patent/BR112021010704A2/en unknown
- 2019-12-04 UA UAA202102856A patent/UA127872C2/en unknown
- 2019-12-04 TW TW108144324A patent/TWI820266B/en active
- 2019-12-04 AU AU2019391942A patent/AU2019391942B2/en active Active
- 2019-12-04 US US17/299,659 patent/US11518763B2/en active Active
- 2019-12-04 EP EP19892751.9A patent/EP3890738A4/en active Pending
- 2019-12-04 MX MX2021006527A patent/MX2021006527A/en unknown
- 2019-12-04 WO PCT/JP2019/048593 patent/WO2020116660A1/en unknown
-
2021
- 2021-05-31 PH PH12021551262A patent/PH12021551262A1/en unknown
- 2021-06-02 CL CL2021001451A patent/CL2021001451A1/en unknown
- 2021-06-03 CO CONC2021/0007304A patent/CO2021007304A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022510736A (en) | 2022-01-27 |
CL2021001451A1 (en) | 2021-12-24 |
CN113164468A (en) | 2021-07-23 |
WO2020116660A1 (en) | 2020-06-11 |
UA127872C2 (en) | 2024-01-31 |
US11518763B2 (en) | 2022-12-06 |
CO2021007304A2 (en) | 2021-06-21 |
MX2021006527A (en) | 2021-07-21 |
PH12021551262A1 (en) | 2021-10-25 |
AU2019391942A1 (en) | 2021-06-03 |
US20220119391A1 (en) | 2022-04-21 |
TWI820266B (en) | 2023-11-01 |
AR117251A1 (en) | 2021-07-21 |
BR112021010704A2 (en) | 2021-08-24 |
EP3890738A4 (en) | 2022-08-17 |
AU2019391942B2 (en) | 2024-03-21 |
EP3890738A1 (en) | 2021-10-13 |
CA3121952A1 (en) | 2020-06-11 |
KR20210099622A (en) | 2021-08-12 |
TW202039494A (en) | 2020-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL271964A (en) | Macrocyclic compounds and uses thereof | |
IL285178A (en) | Compounds and uses thereof | |
IL288991A (en) | Macrocyclic compound and uses thereof | |
EP3826721C0 (en) | Naphthyridine compounds and uses thereof | |
IL285177A (en) | Compounds and uses thereof | |
IL284514A (en) | Halo-allylamine compounds and use thereof | |
IL277502A (en) | Compounds and uses thereof | |
IL286497A (en) | Compounds and uses thereof | |
IL280644A (en) | Magnesium-serinate compound and use thereof | |
IL279483A (en) | Cyanotriazole compounds and uses thereof | |
IL291499A (en) | Aza-quinoline compounds and uses thereof | |
IL284764A (en) | Compounds and uses thereof | |
IL285118A (en) | Compounds and uses thereof | |
SG11202105125XA (en) | Macrocyclic compound and use thereof | |
IL277749A (en) | Pladienolide compounds and their use | |
GB201801102D0 (en) | New compounds and uses | |
EP4051270A4 (en) | 4-amino-imidazoquinoline compounds and use thereof | |
GB201806349D0 (en) | New compounds and uses | |
GB201810121D0 (en) | Macrocyclic compounds and uses thereof | |
IL283540A (en) | Dock1-inhibiting compound and use thereof | |
GB201908967D0 (en) | Macrocyclic compounds and uses thereof | |
ZA202201239B (en) | Aminothiolester compounds and uses thereof | |
SI3683215T1 (en) | Tetrazolinone compound and use thereof | |
GB201810667D0 (en) | New compounds and uses | |
GB201813311D0 (en) | Novel compounds and their use |